You have been told you are not strong enough for chemotherapy. Maybe your doctor said your body cannot tolerate it, or that you are not a good candidate. Someone has since mentioned Lu-177 PSMA therapy, and you want to know whether that door is closed to you as well.
For many older men, the answer is hopeful. Age alone does not determine whether you qualify for Lu-177 PSMA therapy. Neither does a history of being too frail for chemotherapy. What matters is a specific set of health and tumor markers. Real-world evidence shows that older, frailer men can receive this therapy safely and with real benefit.
This article explains what you need to know, in plain language, based on clinical evidence and current approval standards.
Why This Question Matters
Prostate cancer is primarily a disease of older men. Metastatic castration-resistant prostate cancer (mCRPC) — the advanced stage where most men consider Lu-177 PSMA therapy — is often diagnosed in men in their 70s and 80s. This means the patients who need advanced treatment are often the same patients who struggle with traditional chemotherapy.
Chemotherapy works by targeting rapidly dividing cells throughout the entire body, not just in tumors. For an older man with heart disease, weakened kidneys, or other chronic conditions, the side effects can be severe enough that an oncologist decides the risks outweigh the benefits.
Lu-177 PSMA therapy works differently. It is a radioligand therapy (also called targeted radionuclide therapy). A radioactive particle is attached to a molecule that seeks out prostate-specific membrane antigen (PSMA), a protein found in high levels on most prostate cancer cells. This allows the radiation to be delivered close to cancer cells while largely sparing surrounding healthy tissue.
Researchers are asking whether this targeted approach may be better tolerated in older and frailer patients than standard chemotherapy.
Age Alone Is Not a Disqualifier
The first thing to understand is that neither the U.S. Food and Drug Administration (FDA) nor current major medical guidelines set an upper age limit for Lu-177 PSMA therapy. There is no rule that says you must be under 70 or under 75 to be considered.
The FDA approved indications for this therapy focus on three things: whether your cancer is PSMA-positive, your prior treatment history, and a measure of physical fitness called ECOG performance status. Your birth year is not part of the equation.
In the VISION trial — the large Phase 3 study that led to the original 2022 FDA approval — patients simply needed to be 18 years or older. Many trial participants were in their 70s and 80s. The trial required an ECOG performance status of 0 to 2, which is explained in detail below, but set no upper age limit.
Understanding ECOG Performance Status
The key concept for Lu-177 PSMA eligibility is the ECOG Performance Status scale. Oncologists use this tool to measure how well a patient can carry out daily activities. It runs from 0 to 4:
- ECOG 0: Fully active, no restrictions
- ECOG 1: Restricted in strenuous activity but able to walk and do light work
- ECOG 2: Up and about more than half of waking hours; able to care for yourself but not able to do demanding physical work
- ECOG 3: In bed or a chair more than half of waking hours; limited self-care
- ECOG 4: Completely unable to carry out any self-care
Clinical trials for Lu-177 PSMA therapy enrolled patients with ECOG scores of 0, 1, and 2. This is important because a score of 2 describes someone who may tire easily and need help with some daily tasks but is still largely independent day to day.
Chemotherapy is often reserved for patients with ECOG scores of 0 or 1 because it is demanding on the whole body. Because Lu-177 PSMA therapy is targeted rather than systemic, some men who have been told they are too frail for chemotherapy may still have an ECOG score within the range that clinical data supports for this therapy.
If your ECOG score is 3 or 4, treatment becomes riskier. Any active cancer treatment carries higher risk at that level of functional decline, and your care team will need to weigh those risks carefully with you and your family. But for the many men who have been told they cannot handle chemotherapy yet remain largely independent in daily life, asking your doctor about your ECOG score is the right first step.
What Real-World Studies Show About Older Patients
Clinical trials often include younger, healthier patients than the average person living with advanced cancer. Real-world data helps fill that gap. The picture for older patients is encouraging.
A 2025 study examined 312 patients with mCRPC who received Lu-177 PSMA therapy in a real-world clinical setting outside of controlled trials. Among those patients, 24% were older than 75 years. Researchers found no significant difference in progression-free survival or overall survival between patients aged 75 and younger versus those older than 75. Median progression-free survival was 12.7 months in the younger group and 11.7 months in the older group. This difference was too small to be statistically meaningful.
Notably, the older patients in this study more commonly had ECOG scores of 2 or higher, meaning they were on average frailer than the younger patients. Yet they showed comparable cancer-control outcomes. The study authors concluded that Lu-177 PSMA therapy should be considered a safe and important treatment option for elderly patients with mCRPC.
A separate retrospective analysis of age-related outcomes in mCRPC patients receiving this therapy similarly found that age alone was not a meaningful independent predictor of how patients responded when other health factors were accounted for.
These findings do not mean every older man will respond in the same way. Individual health factors, tumor biology, and treatment history all influence outcomes. But the data do show that being old or frail does not automatically keep you from this therapy.
The 2025 Rule Change: You May No Longer Need Prior Chemotherapy
Until March 2025, the FDA-approved use of Lu-177 PSMA therapy required patients to have already received both a type of hormone therapy called an androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy. In practical terms, that requirement formally excluded many frail men — those who could never safely undergo chemotherapy in the first place.
That changed in March 2025. Based on results from the PSMAfore clinical trial, the FDA expanded the approved indication for this therapy. It now covers adults with PSMA-positive mCRPC who have received ARPI hormone therapy and whose oncologist determines it is appropriate to delay taxane-based chemotherapy.
In plain language: if your doctor decides that chemotherapy is not right for you because of age, frailty, heart disease, or another medical reason, that clinical judgment can now make Lu-177 PSMA therapy available to you.
The PSMAfore trial found that patients who received Lu-177 PSMA therapy had a median radiographic progression-free survival of 9.3 months, compared to 5.6 months for those who switched to a different hormone therapy. The Prostate Cancer Foundation noted this expanded approval as an advance for patients with few other options. You can learn more about what this trial data means for earlier treatment access in our article on the PSMAfore trial results and what they mean for Lu-177 PSMA access.
The PSMA PET Scan: The Biological Test You Need First
Before any conversation about age or fitness levels, your cancer must be confirmed as PSMA-positive. This is done through a PSMA PET scan, a specialized imaging test that uses a radioactive tracer to detect how much PSMA protein your cancer cells are expressing.
If the scan shows strong, widespread PSMA expression across your tumors, you meet the key biological criterion for this therapy. If the results are mixed — some lesions showing high PSMA and others showing low or none — your care team will weigh that carefully in their recommendation.
The FDA requires patients to be selected for Lu-177 PSMA therapy using an approved PSMA PET imaging agent. This test is now available at major cancer centers in the United States and at an increasing number of centers internationally, including in India. For a full breakdown of what your scan results mean for eligibility, see our guide: Am I a Candidate for Lu-177 PSMA Therapy? A Plain-Language Eligibility Guide.
Other Health Factors Your Care Team Will Assess
Beyond age and ECOG status, your oncology team will look at several other markers before recommending Lu-177 PSMA therapy. Understanding these in advance can help you have a more informed conversation at your next appointment:
- Kidney function: This therapy is partly cleared through the kidneys. Significant kidney impairment may affect how treatment is planned and monitored. Your team will review your kidney function tests before and during therapy.
- Bone marrow function: Because radiation is involved, your blood cell counts matter. Very low levels of white blood cells, red blood cells, or platelets may lead to delays or adjustments in your treatment schedule.
- Liver involvement: If your liver is significantly affected by cancer spread or by another condition, this will factor into the overall risk assessment.
- Salivary gland health: PSMA protein is also expressed in salivary gland tissue, which means dry mouth is a recognized side effect of this therapy. If you already experience significant dry mouth from other medications, mention this to your care team before starting treatment.
- Cardiovascular health: The 2025 real-world study mentioned earlier found that cardiovascular disease was an independent predictor of worse outcomes in patients receiving Lu-177 PSMA therapy. Heart disease does not automatically disqualify you, but it means a thorough cardiac evaluation will be part of the pre-treatment assessment.
None of these factors is automatically disqualifying. What they do is help your care team design a safe and effective plan for your specific body and situation.
A Word on Bone Pain and Quality of Life
Many men with mCRPC who are too frail for chemotherapy are living with significant bone pain from metastases in their hips, spine, or pelvis. For some, pain management has become the central concern, and they worry there is nothing left to help them feel better if chemotherapy is off the table.
Evidence from the VISION trial suggested that Lu-177 PSMA therapy may help delay worsening of pain and preserve quality of life alongside controlling cancer progression. Bone pain relief is not guaranteed, and results vary by individual, but this potential benefit matters to men dealing with bone pain.
If bone pain is a major part of your situation, this deserves a direct, specific conversation with your oncologist separate from discussions about survival data alone.
When to Talk to Your Doctor
Consider asking your oncologist specifically about Lu-177 PSMA therapy if any of the following apply to you:
- You have been told you are too frail or too old for taxane chemotherapy
- Your prostate cancer has progressed on hormone therapy and is now castration-resistant
- You have not yet had a PSMA PET scan to check whether your tumors express PSMA
- You had a PSMA PET scan with positive results but were told chemotherapy must come first — that requirement changed under the March 2025 FDA update
- You are managing significant bone pain and want to understand all remaining treatment options
Bring a family member or caregiver to your appointment if you can. Ask your doctor directly: what is my current ECOG performance status, is my cancer PSMA-positive, and given the 2025 approval update, am I now eligible for Lu-177 PSMA therapy without prior chemotherapy? For context on the broader treatment picture after hormone therapy stops working, see: My Prostate Cancer Stopped Responding to Hormone Therapy — What Are My Options Before Chemotherapy?
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
Does Lu-177 PSMA therapy require me to have had chemotherapy first?
As of March 2025, not always. The FDA expanded its approved indication to cover patients with PSMA-positive mCRPC who have been treated with ARPI hormone therapy and whose doctor considers it appropriate to delay chemotherapy. If your oncologist has determined chemotherapy is not right for you due to age or frailty, that clinical judgment may now make you eligible rather than ineligible. Ask your doctor specifically about the 2025 approval update and whether it applies to your situation.
What ECOG performance status score do I need to qualify for Lu-177 PSMA therapy?
Clinical trials for Lu-177 PSMA therapy enrolled patients with ECOG performance status scores of 0, 1, and 2. A score of 2 describes someone who rests part of the day but is still largely able to care for themselves. Many oncologists associate chemotherapy with needing ECOG 0 or 1 due to its systemic demands. Lu-177 PSMA therapy may still be considered at ECOG 2, which is why some men deemed too frail for chemo may still be candidates. Ask your doctor what your current ECOG score is.
I am 78 with heart disease and diabetes. Can I still be evaluated for this therapy?
Age, heart disease, and diabetes are not automatic disqualifiers. Real-world studies have included older patients with multiple health conditions. However, cardiovascular disease has been associated with worse outcomes in some data, so your care team will conduct a thorough assessment of your heart health before making a recommendation. Being evaluated at a center with experience in radioligand therapy is important so that all your health factors can be weighed together in a way that is specific to you.
What does a PSMA PET scan show, and do I need one before starting?
Yes. Before starting Lu-177 PSMA therapy, a PSMA PET scan is required to confirm that your cancer cells express the PSMA protein. The scan uses a small amount of radioactive tracer to create images showing where PSMA-positive cancer is located in your body. Strong, widespread PSMA expression across your tumors is a positive sign for eligibility. If the scan shows mixed results, your care team will discuss what that means for your options.
Will older patients respond the same way as younger patients?
Real-world data from a 2025 study of 312 mCRPC patients suggests comparable cancer-control outcomes between patients older and younger than 75. No statistically significant difference in progression-free survival or overall survival was found between the two age groups. However, every patient is different. Your specific tumor biology, kidney function, bone marrow health, and cardiovascular status all play a role in how well you tolerate and respond to treatment. These details should be discussed with your oncologist.
How do I find an oncologist who can evaluate me for Lu-177 PSMA therapy?
You will need a referral to a nuclear medicine physician or a medical oncologist with experience in radioligand therapy. Major cancer centers in the United States and in India are the most common settings. Ask your current urologist or oncologist for a referral to a theranostics or nuclear medicine program. Bring your recent scan records, PSA history, and a list of all prior treatments. Centers experienced in this therapy will typically order a PSMA PET scan as the first step in evaluation.